A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Latest Information Update: 28 Nov 2023
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary hypertension
- Focus Registrational; Therapeutic Use
- Acronyms PERFECT
- Sponsors United Therapeutics Corporation
- 05 Jan 2023 Status changed from active, no longer recruiting to discontinued.
- 02 Nov 2022 According to a United Therapeutics Corporation media release, the company has terminated the study in accordance with a recommendation of the study's independent Data Safety Monitoring Committee (DSMC), following a routine safety and efficacy analysis conducted by the DSMC.
- 07 Oct 2022 Status changed from recruiting to active, no longer recruiting.